Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 20/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155517 | 0.88 | AURKB (0.74) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13155497 | 0.88 | AURKB (0.65) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13155454 | 0.87 | AURKB (0.82) | AURKBCHEK1LCKKDRRPS6KA3 | |
| SCHEMBL13155507 | 0.87 | AURKB (0.74) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13155516 | 0.87 | AURKB (0.74) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13155502 | 0.87 | AURKB (0.74) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13155508 | 0.84 | AURKB (0.64) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13155500 | 0.80 | AURKB (0.56) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL14538361 | 0.78 | AURKB (0.59) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL13617863 | 0.77 | AURKB (1.00) | AURKBCHEK1LCKKDRRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | AURKB 3/4885AURKA 2/4885CHEK1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.